The Manufacturers Life Insurance Company Purchases 27,440 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

The Manufacturers Life Insurance Company grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 32.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 111,613 shares of the company’s stock after acquiring an additional 27,440 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Recursion Pharmaceuticals were worth $837,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Capstone Investment Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $161,000. Benjamin F. Edwards & Company Inc. raised its holdings in Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after acquiring an additional 167,302 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Recursion Pharmaceuticals by 45.2% during the 1st quarter. Russell Investments Group Ltd. now owns 158,305 shares of the company’s stock valued at $1,578,000 after acquiring an additional 49,292 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after purchasing an additional 1,159,023 shares in the last quarter. Finally, Natixis acquired a new position in Recursion Pharmaceuticals in the first quarter valued at about $2,718,000. 89.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the sale, the chief financial officer now owns 1,426,506 shares in the company, valued at $9,015,517.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the transaction, the director now owns 7,155,663 shares of the company’s stock, valued at approximately $60,680,022.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the sale, the chief financial officer now directly owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 201,682 shares of company stock valued at $1,353,652. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $6.62 on Monday. The business has a 50-day simple moving average of $6.69 and a two-hundred day simple moving average of $7.87. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $15.74. The stock has a market cap of $1.86 billion, a PE ratio of -4.09 and a beta of 0.80. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter last year, the company posted ($0.38) earnings per share. The company’s revenue was up 30.9% compared to the same quarter last year. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.